ATLAS HIV treatment study meets primary endpoint

A study into a long-acting, injectable two-drug regimen to treat HIV has met its primary endpoint ViiV healthcare and Janssen Sciences have announced. The positive headline results come from the phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) study. ATLAS was designed to establish if HIV-1-infected adult participants who had maintained viral suppression for at least six months, on a daily oral regimen comprised of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, maintained similar rates of viral suppression upon switching to the investigational, two-drug, long-acting, injectable regimen of cabotegravir and rilpivirine, compared with continuing the three-drug oral